- Home
- LSF vs ALGS Comparison
LSF vs ALGS Comparison
Compare LSF & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | ALGS |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 57.2M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LSF | ALGS |
|---|---|---|
| Price | $2.07 | $11.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $12.00 | ★ $60.00 |
| AVG Volume (30 Days) | ★ 95.9K | 81.5K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,146,862.00 | $2,646,000.00 |
| Revenue This Year | $18.05 | N/A |
| Revenue Next Year | $17.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.73 | N/A |
| 52 Week Low | $2.07 | $3.76 |
| 52 Week High | $8.96 | $46.80 |
Technical Indicators
Market Signals| Indicator | LSF | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 29.58 | 60.78 |
| Support Level | $2.02 | $9.10 |
| Resistance Level | $2.52 | $13.69 |
| Average True Range (ATR) | 0.19 | 0.87 |
| MACD | 0.04 | 0.25 |
| Stochastic Oscillator | 6.58 | 51.10 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.